Articles tagged with Antibodies
Researchers developed an antibody blocking coagulation factor XII, which prevents thrombosis without increasing bleeding risk in clinical settings. This innovation reduces the clotting risk in emergency situations like ECMO treatment and cardiovascular surgery.
Researchers at Yale University found that a combination of hydroxychloroquine may partially reverse the detrimental effects of antiphospholipid antibodies on human placental cell function, potentially benefiting pregnant women with lupus and/or antiphospholipid syndrome. This could lead to improved pregnancy outcomes for these patients.
Researchers have developed a novel DNA-barcoded antibody sensing approach to analyze hundreds of cancer-related protein markers from miniscule patient samples. This technology enables comprehensive analysis of protein expression patterns in single cells, revealing significant differences between tumors and predicting treatment response.
A multinational project led by Dr. Tyler Curiel aims to develop an antibody that can block a specific cancer metabolic pathway and reduce its ability to suppress the immune system.
Researchers at Roche have successfully developed a new technology called Brain Shuttle that efficiently transports investigational antibodies into the brain in preclinical models of Alzheimer's disease. The technology increased target engagement by over 50-fold compared to parent antibodies.
Researchers have successfully constructed a human Fab library and identified a single-domain antibody that specifically targets amyloid-beta 42 oligomers. This breakthrough discovery offers new hope for treating Alzheimer's disease by reducing amyloid-beta burden and improving memory performance.
A Stanford University School of Medicine study found that men with high testosterone levels have a weakened immune response to the flu vaccine, whereas women and men with lower testosterone levels have a stronger response. The study also discovered that testosterone interacts with genes in a way that dampens immune response.
Researchers at LA BioMed developed antibodies to prevent human cell invasion and treat mucormycosis using CotH protein blocker. The study provides groundwork for developing therapies and diagnostic tests for high-risk patients.
Researchers found that HIV-1-specific antibodies and low pH enhance transcytosis of the virus across epithelial cells. This process was enhanced by the FcRn receptor and is influenced by whether or not the antibody neutralizes the virus.
Grand Challenges Canada has awarded $100,000 grants to 83 innovative global health projects addressing disease and healthcare challenges in resource-poor countries. These projects include diagnostic diapers for deadly rotavirus, yogurt-based solutions to pesticide exposure, and storytelling approaches to maternal health.
Researchers have identified the role of the STAT3 gene in immune system memory, revealing how it directs chemical messenger molecules to various destinations. This discovery sheds light on a rare immunodeficiency disorder and may lead to improved vaccines and treatments.
Scientists have discovered an antibody to the protein LRP4, which plays a critical role in enabling the brain to communicate with muscles. This finding explains why some patients with myasthenia gravis may not have any obvious signs of the disease despite having low levels of antibodies.
Researchers found that a specific molecular process controls B cell activation and differentiation, leading to impaired antibody production. The study highlights the importance of genes like IL-21 receptor, STAT3, and CD25 in B cell function, with mutations causing debilitating effects in patients.
A recent study published in Cancer Prevention Research found that women vaccinated with one dose of the human papillomavirus (HPV) vaccine had stable antibodies against HPV viruses in their blood for up to four years. The results challenge previous dogma on protein subunit vaccines requiring multiple doses for long-lived responses.
Berkeley Lab researchers design a programmable nanomaterial inspired by natural antibodies, capable of identifying diverse molecules. The new material resembles 'molecular Velcro' and has promising applications in chemical sensing and catalysis.
Researchers at Nationwide Children's Hospital have found a way to overcome the immune system's attack on gene therapy viruses. By using plasmapheresis, a process that temporarily removes antibodies from the body, they were able to increase gene expression in animals with Duchenne muscular dystrophy by 500 percent.
A recent study highlights the issue of poor antibody performance due to contaminating hitchhiker antigens. This can lead to misdiagnosis, incorrect conclusions about disease mechanisms, and costly mistakes in drug development.
Researchers have discovered a novel way to generate antibodies that target multiple flu viruses, offering new hope for developing a single vaccine against all strains. The study used the immune suppressant rapamycin to shift the immune response and favor production of broadly specific antibodies.
A new study reveals that fewer US adolescents have antibodies against herpes simplex virus type 1 (HSV-1), making them more susceptible to genital infections. The prevalence of HSV-1 antibodies declined among 14-19 year olds by nearly 23% and among 20-29 year olds by over 9%.
Researchers identify novel gene mutation in NFKB2 that impairs antibody production and fight infection, leading to common variable immunodeficiency (CVID). The discovery provides a new mechanism for immune deficiency and enables early diagnosis and treatment.
Chemists at Scripps Research Institute develop new technique to create more stable antibody-drug conjugates, reducing toxicity and increasing efficacy. The new method uses a novel Thiol-Click reaction to form stronger linkages with cysteine amino acids.
Scientists at USC created a mathematical model to predict the biological process creating antibody diversity. The research, a collaboration between Myron Goodman and Chi Mak, explains how an enzyme initiates hypermutations in immunoglobulin genes, generating robust immune systems.
A clinical trial found that a booster dose of the new meningitis B vaccine at 40 months of age can overcome waning immunity induced by infant vaccination, showing high antibody levels in 89%–100% of children against most strains.
A study published in PeerJ found that nearly 50% of scientific resources are unidentifiable due to a lack of detail in journal articles. Researchers developed guidelines for reporting research resources to aid reproducibility, but these did not improve identification rates.
A new recombinant antibody can detect and isolate mesenchymal stem cells (MSCs) from umbilical cord blood, a nonembryonic source with promising applications in tissue engineering and blood stem cell transplantation. The antibody recognizes an i blood group antigen present on MSCs.
Dermatomyositis patients with antibodies against NXP-2 and TIF-1γ have a high risk of cancer, according to new tests developed by researchers. The assays detect these specific proteins in patient blood samples, helping clinicians identify those at highest cancer risk.
Researchers suggest that anti-PD-1 antibodies could be effective in treating hepatitis C and other persistent viral infections. The study found that animal models with HCV infection showed improved immune function after treatment with PD-1 blocking antibodies.
Researchers have developed a new diagnostic approach combining antibody and genetic tests to detect coeliac disease in Australians. The study found that more than half of the population has genetic risk factors for developing coeliac disease.
A new strategy developed at UC Davis Health System tests for telltale antibodies in the blood to detect tuberculosis, potentially improving treatment outcomes. The test can detect about 80% of active TB cases, making it a significant advancement in disease detection.
A study found that piglets receive maternal IgA, IgG and IgM antibodies against Cystoisospora suis in the colostrum, which decline after two weeks. High levels of these antibodies are associated with reduced severity of neonatal diarrhoea.
Researchers found antibodies specific to MERS-CoV in 100% of serum samples from dromedary camels in Oman, but not in animals from other countries. This suggests that a MERS-CoV-like virus is circulating in dromedary camels, potentially serving as an animal reservoir for the human coronavirus.
Researchers tracked the movement of specialized cells to shed light on the immune system's response to invading pathogens. The study found that T follicular helper cells continually move between germinal centers within lymph nodes, potentially enhancing antibody production.
University of Alberta researchers have made a breakthrough in understanding prion protein interactions, paving the way for designing molecules that can block prion infection. The discovery opens up possibilities for treating human victims and preventing livestock diseases such as BSE.
Researchers discover that prion protein has a 'switch' controlling its toxicity, which can be triggered by antibodies targeting the flexible tail. The study finds that only antibodies targeting the tail are suitable for use as potential drugs, while those triggering the switch are harmful.
Researchers at the IRCM isolated two important mechanisms that improve antibody quality, providing a new model for studying auto-immune diseases. The study found that these mechanisms, class switching and affinity maturation, are crucial for immune responses to infections and diseases.
A study published in PLOS ONE found that children with autism have higher levels of gluten antibodies than those without autism. The researchers also discovered an association between the elevated antibodies and gastrointestinal symptoms in affected children. However, no connection was found to celiac disease.
Researchers have found antibodies against the human papillomavirus (HPV) that may help predict individuals at risk of HPV-related oropharyngeal cancer. The study found that these antibodies were detectable in nearly 35% of patients with cancer, compared to less than 1% of those without cancer.
A new study on an anti-nicotine vaccination found mixed results, with some patients experiencing a decrease in brain nicotine accumulation but others showing an increase. The study used PET imaging to test the vaccine's effectiveness, revealing that high-affinity antibodies were associated with decreased brain nicotine accumulation.
Scientists at Scripps Research Institute have identified an extraordinary family of cow antibodies that could lead to breakthroughs in human medicine. The unique structure and mechanism of these antibodies may allow for the creation of new therapeutic proteins.
Traumatic brain injuries generate toxic tau oligomers that cause nerve cells to clump together and spread to other parts of the brain. These damaging protein assemblages can contribute to memory deficits, seizures, and disruptions in the sleep-wake cycle.
Scientists at Emory Vaccine Center found that IL-21 is necessary for long-lasting antibody responses in mice against viral infections. The molecule stimulates germinal centers and supports T helper cells, leading to the generation of virus-specific long-lived plasma cells.
A new study reveals that the level of immunity to the recently circulating H7N9 influenza virus in an urban and rural population in Vietnam is very low. The findings suggest that people living in this area have had little or no exposure to the virus, making it essential to consider alternative plans for pandemic preparedness.
Researchers at Lund University are testing an antibody-based treatment for multiple myeloma, a type of blood cancer without a cure. The antibody, BI-505, has shown promising results in cell studies and animal experiments, and a clinical trial is currently underway to test its effects on patients.
Researchers analyzed data from the RV144 HIV vaccine trial, which showed a 31% protection rate. They found that specific antibodies may interfere with the protective effects of other antibodies, reducing the vaccine's efficacy. This discovery can inform future vaccine development strategies to overcome these limitations.
Research found pregnant women with mid to high levels of anti-tTG antibodies are at risk for having reduced fetal weight and birth weight. Fetuses of women with positive anti-tTG weighed 16 grams less during the second trimester, while those with intermediate anti-tTG levels were 53 grams lighter.
Scientists have developed a new family of selective antimicrobial agents that use synthetic colloid particles to recognize and inactivate specific types of bacteria. These 'colloid antibodies' show promise as a powerful tool against antibiotic-resistant bacteria.
Researchers at Scripps Research Institute found an antibody that directly transforms bone marrow stem cells into neural progenitor cells, a type of almost-mature brain cell. This discovery could lead to simpler and safer cell therapies for treating various conditions.
Researchers discovered that a person's antibody genes, operation, and potential fight-off targets vary from person to person. This study found ethnicity influences immunity, potentially impacting disease risk and treatment responses.
Researchers discovered a genetic deletion in the SMIM1 gene responsible for the Vel blood group, allowing for more accurate DNA testing and reducing the risk of severe reactions during blood transfusions. The study also sheds light on how this gene influences red blood cell traits and haemoglobin levels.
Researchers at Texas Biomedical Institute discovered a polymer hidden within the Ebola virus that can be targeted by llama antibodies, enabling the creation of highly sensitive test kits using a single antibody. This breakthrough may revolutionize emerging viral diagnostics and offer a promising tool for detecting other deadly pathogens.
Researchers at the University of Pennsylvania have developed a nanotube-based diagnostic device that can detect Lyme disease bacteria in the blood, potentially leading to earlier diagnosis and treatment. The device uses laboratory-produced antibodies to bind to proteins from the organism, providing an electronic read-out of its presence.
Researchers identified a unique subset of helper T cells that stimulates protective antibody responses following seasonal influenza vaccinations. The study found that these T cells boost production of existing antibodies by stimulating memory B cells, but do not help produce new antibodies by naïve B cells.
Researchers at Scripps Research Institute developed a cutting-edge technology to screen human blood for disease markers. The 'antigen surrogate' method accurately identified biomarkers for neuromyelitis optica, a rare autoimmune disorder, in a recent study published in Chemistry & Biology.
A team of scientists from the University of Vermont and France has discovered the tiny protein SMIM1, which causes the rare 'Vel-negative' blood type. This breakthrough allows for fast DNA-based tests to identify Vel-negative individuals, enabling them to receive life-saving transusions.
Researchers at the Weizmann Institute of Science created a two-dimensional cell-like system on a glass chip, enabling precise observation of gene expression and protein behavior. The system allows for the simultaneous production and trapping of multiple proteins, revealing a spectrum of protein activities.
Researchers found that B cells improve antibody molecules through a process of somatic hypermutation, increasing selection pressure on their own products. This mechanism could accelerate vaccination methods by producing optimal antibodies earlier.
Researchers found that even routine hits can impact the blood-brain barrier and lead to an immune response. The study suggests a possible vaccine or drug therapy to prevent head trauma, offering new insights into concussions and their long-term consequences.
Pediatric kidney transplant recipients with antibodies are more likely to experience kidney injury and rejection. Steroids do not prevent this antibody-mediated injury, but monitoring recipients for antibodies and customizing immunosuppressive treatments can help.
A team led by Dr. Marie-Josée Hébert discovered a new class of antibodies - anti-LG3 - which can trigger severe rejection episodes and high organ loss rates in kidney transplant patients. This breakthrough holds promise for developing new therapies to prevent or limit organ rejection.
Researchers at Duke University Medical Center identified a defect in bladder immune memory that hampers a timely attack against bacterial infections. The study found that mast cells produce an immune-suppressing molecule, leading to a lack of antibody response and stifling immune memory.